In the race to innovate, life sciences companies are betting big on M&A, but navigating the risks requires smarter deal structures Big pharmaceutical companies facing patent cliffs. MedTech companies seeking access to the latest AI technologies. Across the life sciences industry, companies have strong incentives to use M&A to grow their product pipelines, enhance their existing product offerings, and gain access to new markets. But, at what cost? Less than half of phase II clinical…
Commission enacts first Implementing Regulation under the EU’s International Procurement Instrument – and the Chinese Government promptly retaliates For the first time, the European Commission completed an investigation under the International Procurement Instrument (IPI) and implemented measures to limit the participation of economic operators from non-EU countries – in this particular case, China – in the EU public procurement market. After EU suppliers of medical devices have arguably been denied fair access to Chinese government…
